New sleep aid studied for those with mental illness

NCT ID NCT07417813

Recruiting now Symptom relief Sponsor: Shanghai Mental Health Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well and how safely a new sleep medication, lemborexant, works for people who have both a mental health condition and trouble sleeping. About 121 adults will take the drug for 8 weeks, and researchers will track changes in their sleep quality and any side effects. The goal is to find better ways to treat insomnia in people with psychiatric disorders.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INSOMNIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

insomnia psychiatric disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INSOMNIA PSYCHIATRIC DISORDERS

Contacts and locations

Locations

Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, 200120, China
Shanghai Fengxian District Mental Health Center
RECRUITING

Shanghai, Shanghai Municipality, 201400, China
Shanghai Mental Health Center
RECRUITING

Shanghai, Shanghai Municipality, 200030, China
Shanghai Pudong New Area Mental Health Center
RECRUITING

Shanghai, Shanghai Municipality, 200120, China
Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310000, China
Suzhou GuangJi Hospital
RECRUITING

Suzhou, Jiangsu, 215000, China
The First Affiliated Hospital of Ningbo University
RECRUITING

Ningbo, Zhejiang, 315000, China
The Second Affiliated Hospital of Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310000, China
Xuzhou Oriental People's Hospital
RECRUITING

Xuzhou, Jiangsu, 221000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.